“Clonal Hematopoiesis: Implications for Cardiology, Neurology, Oncology and Beyond” (Hybrid Event)

David P. Steensma, MD FACP
Chief Medical Officer
Ajax Therapeutics, MD

Dr. David Steensma is currently the Chief Medical Officer of Ajax Therapeutics.  Previously he was Global Hematology Head at Novartis Institutes for BioMedical Research in Cambridge, Massachusetts, leading early development across non-malignant and malignant hematology.  Until December 2020, he was Edward P. Evans Chair in Myelodysplastic Syndromes in the Division of Hematological Malignancies and Department of Medical Oncology at Dana-Farber Cancer Institute (DFCI), and a faculty member at Harvard Medical School (HMS).  He directed the Center for Prevention of Progression at DFCI for patients with clonal hematopoiesis and other hematological malignancy precursor conditions, led clinical research efforts at DFCI in myelodysplastic syndromes (MDS), and was the founding clinical director of the Regenerative Medicine and Stem Cell Biology advanced integrated scientific and clinical course at HMS.

___________________________________________________________________

Join Meeting!

OBJECTIVES:

• Analyze that mutations in leukemia-associated genes are commonly detected in healthy older people and confer a wide range of health risks
• Explain clinical consequences of clonal hematopoiesis
• Assess potential therapeutic approaches to clonal hematopoiesis

FACULTY DISCLOSURES:

Dr. Steensma has indicated the following relevant financial relationships with commercial interests:

Financial Relationship                                     Commercial Interest/Organization
Employee                                                              Novartis, Ajax Therapeutics
Individual Stocks                                                    Bluebird, Arrowhead, Gamida Cell
Ownership Interest                                                Ajax Therapeutics

PLANNING COMMITTEE DISCLOSURE:

Dr. Deshpande has indicated that he has no relevant financial relationships with commercial interests.
Dr. Weiss has indicated the following relevant financial relationships with commercial interests:

Financial Relationship                                     Commercial Interest/Organization
Consultant/Contractor                                           Prizm LLC

All the relevant financial relationships for these individuals have been mitigated.

TARGET AUDIENCE:
Primary care physicians.

ACCREDITATION:
The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:
The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.